“No doubts about Abramson’s basic revelations but there are safe guards: For example:
The power of the pen: Providers can be more judicious in prescribing drugs as a first line approach and should be a steward as far as discontinuing ones that aren’t giving sufficient benefit for whatever reason. No drug is without a downside. Many people are nonadherent with them anyway. Prescribers are aware of drug rep motivations and I doubt they are watching TV ads but when a patient wants that new medication:
Insurance companies kick in: they prefer to pay for cheaper older drugs and typically require the prescriber jump through a bunch of hoops to get the newer ones accepted for payment
Particularly agree that clinical guidelines are part of the problem related to liability dodging increasing investigative procedures ordering treatments etc in addition to prescribing even when there is a low level of suspicion or adequate risk benefit. Guidelines also promote up charging on healthcare visits by medical systems which affects the insured directly due to ridiculous deductibles.”
michkatel via Apple Podcasts ·
United States of America ·
08/10/22